VANCOUVER, BC—October 20, 2009: Xenon Pharmaceuticals Inc. (Xenon) and the Centre for Drug Research and Development (CDRD) today announced a strategic collaboration between Xenon and CDRD’s commercial arm, Drug Development Inc. (DDI).
“Our goal with this collaboration is to advance an early-stage R&D program by leveraging the technical strengths and research capabilities established by CDRD and DDI,” said Simon Pimstone, President and CEO of Xenon.
“This is a great opportunity to demonstrate DDI’s ability to collaborate with the local lifesciences and biotech industry. We intend to assist Xenon in reaching its early stage research goals by offering a high level of R&D expertise, as well as adding value by expediting certain early stage research milestones in this Xenon program,” said Natalie Dakers, Chief Executive Officer for CDRD and DDI.
About CDRD and DDI
The Centre for Drug Research and Development (CDRD) guides and supports early-stage drug development from BC’s top academic and health research institutions to increase the successful commercialization of new therapeutics. CDRD provides drug development expertise and infrastructure to enable researchers throughout BC to develop promising drug candidates. CDRD’s commercial arm, Drug Development Inc (DDI), licenses technologies from affiliated institutions, advances projects by leveraging CDRD’s expertise and infrastructure, and establishes working collaborations with other biotech and lifesciences companies. For more information, visit CDRD’s website.
About Xenon
Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies based on the genetic causes of select metabolic, neurological and cardiovascular diseases. For more information, visit the Company’s website.
For additional information, contact:
CDRD
Jodi Regts
Director, Communications
(604) 221-7750 x182
jregts@cdrd.ca
Xenon
Dr. Robin Sherrington
Senior Director, Strategic Alliances
(604) 484-3363
ddunn@xenon-pharma.com
This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.